БЭЙТМЭН Никола Фрэнсис (GB),МАКФАУЛ Филип Александер (GB),НЭШ Айан Алун (GB)
申请号：
RU2010143985/15
公开号：
RU2010143985A
申请日:
2009.04.09
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. A pharmaceutical depot containing (1) N- {5 - [(cyclopropylamino) carbonyl] -2-methylphenyl} -3-fluoro-4- (pyridin-2-ylmethoxy) benzamide or a pharmaceutically acceptable salt thereof as a pharmaceutical agent ( PA) and (2) a polymer that decomposes to create an acidic microclimate, where RA is released from the polymer upon polymer decomposition. ! 2. The pharmaceutical depot according to claim 1, where the polymer is selected from a polyester of fatty hydroxyacid and its derivatives, a polymer of alkyl-α-cyanoacrylate, polyalkylene oxalate, poly-ortho-ester, polycarbonate, poly-ortho-carbonate, polyamino acid, hyaluronic acid ester and their mixtures. ! 3. The pharmaceutical depot according to claim 2, where the polymer is a lactic acid-glycolic acid copolymer. ! 4. The pharmaceutical depot according to claim 3, where the lactic acid-glycolic acid copolymer has a lactic acid: glycolic acid molar ratio in the range from 100: 0 to 50:50. ! 5. The pharmaceutical depot according to claim 4, where the lactic acid-glycolic acid copolymer has a lactic acid: glycolic acid molar ratio of 95: 5. ! 6. The pharmaceutical depot according to claim 4, where the lactic acid-glycolic acid copolymer has a molar acid: glycolic acid molar ratio of 50:50. ! 7. The pharmaceutical depot according to claim 1, where the pharmaceutical depot is made for the controlled and / or continuous release of RA over a period of from about 30 to 90 days. ! 8. The pharmaceutical depot according to claim 7, where the pharmaceutical depot is made for the controlled and / or continuous release of RA over a period of about 30 days. ! 9. The pharmaceutical depot according to claim 7, where the pharmaceutical depot is made for controlled and / or1. Фармацевтическое депо, содержащее (1) N-{5-[(циклопропиламино)карбонил]-2-метилфенил}-3-фтор-4-(пиридин-2-илметокси)бензамид или его фармацевтически приемлемую соль в качестве фармацевтического агента (РА) и (2) полимер, который разлагается с созданием кислого
